A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...

Sun Pharma to acquire Checkpoint Therapeutics, expanding innovative portfolio in onco-derm therapy with FDA-approved UNLOXCYT ...

The upfront cash payment of $4.10 per share of common stock represents a premium of around 66% to Checkpoint’s closing share ...

(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...